Aigen Investment Management LP Takes Position in Genmab A/S (NASDAQ:GMAB)

Aigen Investment Management LP bought a new position in Genmab A/S (NASDAQ:GMAB - Free Report) in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor bought 35,889 shares of the company's stock, valued at approximately $1,143,000.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Assetmark Inc. increased its stake in Genmab A/S by 6.4% in the 4th quarter. Assetmark Inc. now owns 43,518 shares of the company's stock valued at $1,386,000 after buying an additional 2,636 shares during the last quarter. Trexquant Investment LP bought a new stake in Genmab A/S during the fourth quarter worth $4,875,000. PNC Financial Services Group Inc. boosted its position in Genmab A/S by 5.4% in the fourth quarter. PNC Financial Services Group Inc. now owns 165,187 shares of the company's stock worth $5,260,000 after purchasing an additional 8,463 shares during the last quarter. Torray Investment Partners LLC grew its stake in Genmab A/S by 2.6% in the 4th quarter. Torray Investment Partners LLC now owns 107,201 shares of the company's stock valued at $3,413,000 after purchasing an additional 2,685 shares during the period. Finally, Envestnet Portfolio Solutions Inc. increased its position in shares of Genmab A/S by 32.7% during the 4th quarter. Envestnet Portfolio Solutions Inc. now owns 27,122 shares of the company's stock valued at $864,000 after purchasing an additional 6,681 shares during the last quarter. Hedge funds and other institutional investors own 7.07% of the company's stock.

Wall Street Analyst Weigh In

GMAB has been the topic of a number of research analyst reports. HC Wainwright reissued a "buy" rating and issued a $50.00 price target on shares of Genmab A/S in a report on Monday. Morgan Stanley reissued an "underweight" rating on shares of Genmab A/S in a report on Tuesday, March 26th. Citigroup lowered Genmab A/S from a "neutral" rating to a "sell" rating in a research note on Monday, January 22nd. Truist Financial reiterated a "buy" rating and set a $50.00 price target on shares of Genmab A/S in a research note on Tuesday, March 26th. Finally, BMO Capital Markets raised shares of Genmab A/S from a "market perform" rating to an "outperform" rating and upped their price objective for the company from $46.00 to $48.00 in a report on Friday, February 23rd. Three investment analysts have rated the stock with a sell rating, two have assigned a hold rating and eight have given a buy rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Hold" and a consensus target price of $48.50.

Genmab A/S Stock Performance

Genmab A/S stock traded down $0.54 during midday trading on Tuesday, reaching $29.15. 335,499 shares of the stock were exchanged, compared to its average volume of 577,933. The company's fifty day moving average is $29.39 and its 200-day moving average is $29.93. Genmab A/S has a 52 week low of $26.32 and a 52 week high of $42.72. The firm has a market cap of $19.27 billion, a PE ratio of 24.29, a PEG ratio of 1.36 and a beta of 1.00.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.